Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy

Grants

Funding Acknowledgements

We thank all the individuals who took part in these studies and all the researchers, clinicians, technicians, and administrative staff who have enabled this work to be carried out. This study would not have been possible without the contributions of the following: Kyriaki Michailidou, (BCAC), Andrew Berchuck (OCAC), Rosalind A Eeles, Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Antonis Antoniou, Lesley McGuffog and Ken Offit (CIMBA), Andrew Lee, Ed Dicks, Graig Luccarini and the staff of the Centre for Genetic Epidemiology Laboratory, Anna Gonzalez-Neira and the staff of the CNIO genotyping unit, Jacques Simard and Daniel C Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissiSre and Frederic Robidoux and the staff of the McGill University and Gnome Qubec Innovation Centre, Stig E. Bojesen, Sune F Nielsen, Borge G Nordestgaard, and the staff of the Copenhagen DNA laboratory, and Julie M Cunningham, Sharon A Windebank, Christopher A Hilker, Jeffret Meyer and the staff of Mayo Clinic Genotyping Core Facility. ABCS would like to thank Annegien Broeks, Emiel Rutgers, Laura vanat Veer, Richard van Hien, Frans Hogervorst, Senno Verhoef. HEBCS would like to thank Kirsimari Aaltonen, Karl von Smitten, Sofia Khan, Tuomas Heikkinen and Irja Erkki KBCP thanks Eija Myohanen and Helena Kemilainen. LMBC thanks Gilian Peuteman, Dominiek Smeets, Thomas Van Brussel and Kathleen Corthouts. MARIE thanks Judith Heinz, Nadia Obi, Alina Vrieling, Muhabbet Celik, Til Olchers and Stefan Nickels. NBCS would like to thank the following clinical collaborators: Professor Per Eystein Lonning, MD (Section of Oncology, Institute of Medicine, University of Bergen and Department of Oncology, Haukeland University Hospital, Bergen, Norway), Professor Emeritus Sophie D Foss, MD (National Resource Centre for Long-term Studies after Cancer, Rikshospitalet-Radiumhospitalet Cancer Clinic Montebello, Oslo, Norway), Head physician Tone Ikdahl, MD (Department of Oncology, Oslo University Hospital, Oslo, Norway), Dr Lars Ottestad, MD (Department of Genetics and Department of Oncology, Oslo University Hospital Radiumhospitalet), Dr Marit Muri Holmen, MD (Department of Radiology, Oslo University Hospital Radiumhospitalet, Oslo, Norway), Dr Vilde Haakensen, MD (Department of Genetics and Department of Oncology, Oslo University Hospital Radiumhospitalet and Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway), Professor Bjorn Naume, MD (Division of Cancer Medicine and Radiotherapy, Department of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway), Professor Eiliv Lund (Department of Community Medicine, Faculty of Health Sciences, University of Tromso - The Arctic University of Norway, Tromso, Norway), Associate Professor slaug Helland, MD (Department of Genetics, Institute for Cancer Research and Department of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway), Professor Inger Torhild Gram, MD (Department of Community Medicine, Faculty of Health Sciences, University of Tromso and Norwegian Centre for Integrated Care and Telemedicine, University Hospital of North Norway, Tromso, Norway), Professor Emeritus Rolf Karesen, MD (Department of Breast and Endocrine Surgery, Institute for Clinical Medicine, Ullevaal Hospital, Oslo University Hospital and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway), Dr.Ellen Schlichting, MD (Department for Breast and Endocrine Surgery, Oslo University Hospital Ullevaal, Oslo, Norway), Professor Toril Sauer, MD (Department of Pathology at Akershus University hospital, Lorenskog, Norway), Dr Olav Engebrten, MD (Institute for Clinical Medicine, Faculty of Medicine, University of Oslo and Department of Oncology, Oslo University Hospital, Oslo, Norway), Dr Margit Riis, MD (Department of Surgery, Akershus University Hospital and Department of Clinical Molecular Biology (EpiGen), Institute of Clinical Medicine, Akershus University Hospital, University of Oslo, Lorenskog, Norway). OFBCR thanks Teresa Selander and Nayana Weerasooriya. PBCS thanks Louise Brinton, Neonila Szeszenia-Dabrowska, Beata Peplonska, Witold Zatonski, Pei Chao and Michael Stagner, RBCS would like to thank Petra Bos, Jannet Blom, Ellen Crepin, Elisabeth Huijskens, Annette Heemskerk and the Erasmus MC Family Cancer Clinic. SASBAC would like to thank the Swedish Medical Research Counsel. SEARCH thanks Craig Luccarini, Caroline Baynes, Don Conroy, Anne Stafford, Sue Irvine, Barbara Perkins, Val Rhenius. SKKDKFZS thank all study participants, clinicians, family doctors, researchers and technicians for their contributions and commitment to the study. kConFab/AOCS wish to thank Heather Thorne, Eveline Niedermayr, Charmaine Smith, Sandra Picken, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the kConFab Follow Up Study for their contributions to this resource, and the many families who contribute to kConFab. MYBRCA thanks Phuah Sze Yee, Peter Kang, Kang In Nee, Kavitta Sivanandan, Shivaani Mariapun, Yoon Sook-Yee, Daphne Lee and Teh Yew Ching for DNA extraction and patient recruitment. Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement number 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The BCAC is funded by CR-UK (C1287/A10118 and C1287/A12014). Meetings of the BCAC have been funded by the European Union COST program (BM0606). The ABCS study was supported by the Dutch Cancer Society (grants NKI 2007-3839; 2009 4363); BBMRI-NL, which is a Research Infrastructure financed by the Dutch government (NWO 184.021.007); and the Dutch National Genomics Initiative. The work of the BBCC study was partly funded by ELAN-Fond of the University Hospital of Erlangen. The HEBCS study was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, The Nordic Cancer Union and the Sigrid Juselius Foundation. Financial support for KARBAC study was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institute, the Swedish Cancer Society, The Gustav V Jubilee foundation and Bert von Kantzows foundation.The KBCP study was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, and by the strategic funding of the University of Eastern Finland. The LMBC study is supported by the Stichting tegen Kanker (232-2008 and 196-2010). The MARIE study was supported by the Deutsche Krebshilfe e.V. (70-2892-BRI, 106332, 108253, 108419), the Hamburg Cancer Society, the German Cancer Research Center and the Federal Ministry of Education and Research (BMBF) Germany (01KH0402). The MCBCS study was supported by the NIH grants CA128978, CA116167, CA176785 and NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), and the Breast Cancer Research Foundation and a generous gift from the David F and Margaret T Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation. The NBCS study was supported by grants from the Norwegian Research council, 155218/V40, 175240/S10 to ALBD, FUGE-NFR 181600/V11 to VNK and a Swizz Bridge Award to ALBD. The OFBCR study was supported by grant UM1 CA164920 from the National Cancer Institute (USA). The PBCS study was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The RBCS study was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). The SASBAC study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health (NIH) and the Susan G Komen Breast Cancer Foundation. The SEARCH study is funded by a program grant from Cancer Research UK (C490/A10124)] and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. The SKKDKFZS study is supported by the German Cancer Research Center. The kConFab study is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. The kConFab follow-up study has received funding from the NHMRC, the National Breast Cancer Foundation, Cancer Australia, and the National Institute of Health (USA). KAP is a National Breast Cancer Foundation Fellow (Australia). The HERPACC study was supported by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science, Sports, Culture and Technology of Japan, by a Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from Ministry Health, Labour and Welfare of Japan, by Health and Labour Sciences Research Grants for Research on Applying Health Technology from Ministry Health, Labour and Welfare of Japan and by National Cancer Center Research and Development Fund. The MYBRCA study is funded by research grants from the Malaysian Ministry of Science, Technology and Innovation (MOSTI), Malaysian Ministry of Higher Education (UM.C/HlR/MOHE/06) and Cancer Research Initiatives Foundation (CARIF). Additional controls were recruited by the Singapore Eye Research Institute, which was supported by a grant from the Biomedical Research Council (BMRC08/1/35/19/550), Singapore and the National medical Research Council, Singapore (NMRC/CG/SERI/2010).The SEBCS study was supported by the BRL (Basic Research Laboratory) program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2012-0000347). The TWBCS study is supported by the Taiwan Biobank project of the Institute of Biomedical Sciences, Academia Sinica, Taiwan. The POSH study was supported by Funding Breast Cancer Campaign (NOV210PR62) and Cancer Research UK (C1275/A9896). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. Douglas F Easton is a Principal Research Fellow of Cancer Research UK. The funders had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript.